TRIM9

Across TCGA pan-cancer cohorts, TRIM9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TRIM9 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TRIM9 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TRIM9 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, CCRCC, and LSCC are the cancer types where TRIM9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	1.000	0.689	.006	18	view →
CCRCC	OS	Quartile	All	0.652	0.912	.004	16	view →
LSCC	DFS	Median	II,III,IV	0.190	0.892	.024	8	view →
LUAD	OS	Tertile	All	0.572	0.983	.025	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TRIM9–HNSC (OS)

Open the HNSC breakdown →